SARS-CoV-2 serosurvey in health care workers of the Veneto Region

Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investi...

Full description

Saved in:
Bibliographic Details
Published inClinical chemistry and laboratory medicine Vol. 58; no. 12; pp. 2107 - 2111
Main Authors Plebani, Mario, Padoan, Andrea, Fedeli, Ugo, Schievano, Elena, Vecchiato, Elena, Lippi, Giuseppe, Lo Cascio, Giuliana, Porru, Stefano, Palù, Giorgio
Format Journal Article
LanguageEnglish
Published Germany De Gruyter 26.08.2020
Walter De Gruyter & Company
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs). Methods Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China). Results A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1-5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects. Conclusions Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers.
AbstractList Abstract Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs). Methods Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China). Results A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1–5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects. Conclusions Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers.
The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs).Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China).A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1–5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects.Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers.
Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges to all health care systems. Serological assays may be used for improving disease management when appropriately applied, for investigating the antibody responses mounted against SARS-CoV-2 infection and for assessing its real prevalence. Although testing the whole population is impractical, well-designed serosurveys in selected subpopulations in specific risk groups may provide valuable information. We evaluated the prevalence of SARS-CoV-2 infection in health care workers (HCW) who underwent molecular testing with reverse transcription real-time polymerase chain reaction (rRT-PCR) in the main hospitals of the Veneto Region of Italy by measuring specific antibodies (Abs). Methods Both immunoglobulin (Ig)M and IgG antibodies against SARS-Cov-2 S-antigen and N-protein were measured using a validated chemiluminescent analytical system (CLIA) called Maglumi™ 2000 Plus (New Industries Biomedical Engineering Co., Ltd [Snibe], Shenzhen, China). Results A total of 8,285 HCW were tested. SARS-CoV-2 specific antibodies (IgM, IgG or both) were detectable in 378 cases (4.6%, 95% CI 4.1-5.0%). Seroconversion was observed in 4.4% of women vs. 5.0% of men, but this difference was not significant. Although detectable antibodies were found in all HCW who developed severe COVID-19 infection (100%), lower seropositivity was found in mild disease (83%) and the lowest prevalence (58%) was observed in asymptomatic subjects. Conclusions Seroprevalence surveys are of utmost importance for understanding the rate of population that has already developed antibodies against SARS-CoV-2. The present study defined precisely the circulation of SARS-CoV-2 in a cohort of HCW in the Veneto Region, with its prevalence (4.6%) reflecting a relatively low circulation. Symptomatic individuals or those hospitalized for medical care were 100% antibody positive, whilst Abs were only detectable in 58% of asymptomatic carriers.
Author Fedeli, Ugo
Padoan, Andrea
Lo Cascio, Giuliana
Porru, Stefano
Plebani, Mario
Schievano, Elena
Palù, Giorgio
Lippi, Giuseppe
Vecchiato, Elena
Author_xml – sequence: 1
  givenname: Mario
  orcidid: 0000-0002-0270-1711
  surname: Plebani
  fullname: Plebani, Mario
  email: mario.plebani@unipd.it
  organization: Department of Medicine-DIMED, University of Padova, Padova, Italy
– sequence: 2
  givenname: Andrea
  orcidid: 0000-0003-1284-7885
  surname: Padoan
  fullname: Padoan, Andrea
  organization: Department of Medicine-DIMED, University of Padova, Padova, Italy
– sequence: 3
  givenname: Ugo
  surname: Fedeli
  fullname: Fedeli, Ugo
  organization: Epidemiological Department, Azienda Zero, Veneto Region, Padova, Italy
– sequence: 4
  givenname: Elena
  surname: Schievano
  fullname: Schievano, Elena
  organization: Epidemiological Department, Azienda Zero, Veneto Region, Padova, Italy
– sequence: 5
  givenname: Elena
  surname: Vecchiato
  fullname: Vecchiato, Elena
  organization: Department of Information Technology, Azienda Zero, Veneto Region, Padova, Italy
– sequence: 6
  givenname: Giuseppe
  orcidid: 0000-0001-9523-9054
  surname: Lippi
  fullname: Lippi, Giuseppe
  organization: Section of Clinical Biochemistry, University of Verona, Verona, Italy
– sequence: 7
  givenname: Giuliana
  surname: Lo Cascio
  fullname: Lo Cascio, Giuliana
  organization: Department of Microbiology and Virology, University of Verona, Verona, Italy
– sequence: 8
  givenname: Stefano
  surname: Porru
  fullname: Porru, Stefano
  organization: Department of Diagnostics and Public Health, University of Verona, Verona, Italy
– sequence: 9
  givenname: Giorgio
  surname: Palù
  fullname: Palù, Giorgio
  organization: University of Padova, Azienda Zero, Veneto Region, Padova, Italy
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32845861$$D View this record in MEDLINE/PubMed
BookMark eNptkE1rGzEQhkVJqZO01x6DIJdclGr0sdq9BIzJR8FQiFtfl13tKLazXiXSboL_fbS120DpaebwzDszzwk56nyHhHwFfgka9Ddr2y0TXHAGQmYfyDEoaZiSEo5-94plmYAJOYlxwzlorcwnMpEiVzrP4JhMF9P7BZv5JRM0YvBxCC-4o-uOrrBq-xW1VUD66sMjhki9o_0K6RI77D29x4e17z6Tj65qI3451FPy6-b65-yOzX_cfp9N58xqKXpmaqilFFo3RudV0whAx2trramVRFU465SDTDZCF-iyAmrrascrwzObF9bIU3Kxz30K_nnA2JfbdbTYtlWHfoilSI_nqigKSOj5P-jGD6FL1yVK58JkHMbAyz1l09sxoCufwnpbhV0JvBzllqPccpRbjnLTwNkhdqi32PzF_9hMwNUeeE3qMDT4EIZdat7X_z9Z5yAEcCPfAIx2iZ4
CitedBy_id crossref_primary_10_1038_s41598_021_89877_y
crossref_primary_10_1515_almed_2023_0008
crossref_primary_10_1016_j_puhe_2021_07_029
crossref_primary_10_2478_pjph_2022_0001
crossref_primary_10_4103_jfmpc_jfmpc_288_21
crossref_primary_10_1001_jamanetworkopen_2021_15699
crossref_primary_10_1136_bmjopen_2020_046276
crossref_primary_10_1016_j_idh_2021_03_004
crossref_primary_10_3390_vaccines9080824
crossref_primary_10_1016_j_infpip_2023_100297
crossref_primary_10_1371_journal_pone_0264964
crossref_primary_10_1002_eji_202049058
crossref_primary_10_1515_chem_2023_0364
crossref_primary_10_3390_idr13030067
crossref_primary_10_3390_v14122652
crossref_primary_10_1016_j_ebiom_2020_103087
crossref_primary_10_33631_duzcesbed_849590
crossref_primary_10_3390_biomedicines11010160
crossref_primary_10_1016_j_jhin_2021_04_021
crossref_primary_10_1515_labmed_2021_0107
crossref_primary_10_1097_j_pbj_0000000000000166
crossref_primary_10_1177_0300891620974755
crossref_primary_10_1016_j_eclinm_2021_100770
crossref_primary_10_1136_bmjopen_2020_047010
crossref_primary_10_1097_QCO_0000000000000734
crossref_primary_10_1016_j_ijid_2021_09_023
crossref_primary_10_3390_ijerph18073343
crossref_primary_10_1515_cclm_2021_0038
crossref_primary_10_3389_fmed_2021_689994
crossref_primary_10_3390_vaccines8040778
crossref_primary_10_1097_MD_0000000000032992
crossref_primary_10_1515_cclm_2020_1758
crossref_primary_10_1038_s41598_021_89014_9
crossref_primary_10_1136_bmjopen_2021_052130
crossref_primary_10_3390_v15040955
crossref_primary_10_3390_v13061064
crossref_primary_10_3390_ijerph18126446
crossref_primary_10_1515_cclm_2020_1681
crossref_primary_10_1038_s41598_021_04279_4
crossref_primary_10_1016_j_ebiom_2021_103259
crossref_primary_10_3390_ijerph18094761
crossref_primary_10_1111_all_15047
crossref_primary_10_1515_almed_2023_0036
crossref_primary_10_1017_S0950268822000280
crossref_primary_10_3390_ijerph18052567
crossref_primary_10_3390_v13020347
crossref_primary_10_2139_ssrn_3907251
crossref_primary_10_1016_j_jhin_2020_11_008
crossref_primary_10_3390_ijerph18084376
crossref_primary_10_1515_cclm_2022_0948
Cites_doi 10.1001/jamainternmed.2020.4214
10.7326/M20-1301
10.1515/cclm-2020-0443
10.1101/2020.03.16.20035014
10.1001/jama.2020.14765
10.1126/science.abc1227
10.1093/labmed/lmaa025
10.1038/s41591-020-0897-1
10.1515/cclm-2020-0749
10.1016/j.it.2020.03.007
10.1001/jama.2020.11160
10.1016/j.cell.2020.05.015
10.1001/jama.2020.4683
10.1016/j.cca.2020.04.026
10.1001/jama.2020.8259
10.1056/NEJMc2011599
10.1093/cid/ciaa310
10.1038/s41591-020-0913-5
10.1515/cclm-2020-0473
10.1515/cclm-2020-0880
10.2807/1560-7917.ES.2020.25.10.2000180
10.1101/2020.05.12.20098236
10.1016/j.jcv.2020.104545
10.1016/S1473-3099(20)30196-1
10.2139/ssrn.3546052
10.1016/j.cca.2020.05.050
10.1515/cclm-2020-1096
10.1101/2020.04.17.20061440
10.2807/1560-7917.ES.2020.25.3.2000045
ContentType Journal Article
Copyright 2020. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2020. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QO
7T7
7TK
7U7
8FD
C1K
FR3
P64
7X8
DOI 10.1515/cclm-2020-1236
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Biotechnology Research Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Toxicology Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Biotechnology Research Abstracts
Technology Research Database
Toxicology Abstracts
Engineering Research Database
Industrial and Applied Microbiology Abstracts (Microbiology A)
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList CrossRef
Biotechnology Research Abstracts
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
EISSN 1437-4331
EndPage 2111
ExternalDocumentID 10_1515_cclm_2020_1236
32845861
10_1515_cclm_2020_123658122107
Genre Journal Article
GeographicLocations Italy
GeographicLocations_xml – name: Italy
GroupedDBID ---
0R~
0~D
29B
354
36B
4.4
53G
5GY
5RE
AAAEU
AABBZ
AAEMA
AAFPC
AAGVJ
AALGR
AAOQK
AAOWA
AAPJK
AAQCX
AASQH
AAXCG
ABAOT
ABAQN
ABFKT
ABFQV
ABIQR
ABLJU
ABMIY
ABPLS
ABPTK
ABRDF
ABUVI
ABXMZ
ABYBW
ACEFL
ACGFS
ACIWK
ACPRK
ACTFP
ACZBO
ADDWE
ADEQT
ADGQD
ADGYE
ADOZN
AEDGQ
AEGVQ
AEICA
AEJTT
AENEX
AEQDQ
AERZL
AEXIE
AFBAA
AFBQV
AFCXV
AFGDO
AFQUK
AFRAH
AFYRI
AHOVO
AHVWV
AHXUK
AIERV
AIGSN
AJATJ
AJHHK
ALMA_UNASSIGNED_HOLDINGS
ALUKF
ASYPN
BAKPI
BBCWN
BCIFA
CAG
CGQUA
CS3
DBYYV
DU5
EBS
EMOBN
F5P
HZ~
ITC
IY9
M48
N9A
O9-
OBC
OBS
OEB
OES
OHH
P2P
PQEST
PQQKQ
QD8
RDG
SA.
UK5
WTRAM
ZA5
AAILP
ABJNI
ABVMU
ABWLS
ACPMA
AGBEV
AKXKS
ALYBR
CGR
CUY
CVF
ECM
EIF
KDIRW
NPM
SLJYH
TEORI
AAYXX
CITATION
7QO
7T7
7TK
7U7
8FD
C1K
FR3
P64
7X8
ID FETCH-LOGICAL-c532t-7b1b33255d758add21ef0bccc7b43e49fcf4f163d259ef691bcfbf0a706c89c73
ISSN 1434-6621
IngestDate Fri Oct 25 10:56:21 EDT 2024
Thu Oct 10 20:29:32 EDT 2024
Thu Sep 26 17:15:01 EDT 2024
Sat Sep 28 08:29:26 EDT 2024
Fri Nov 25 00:39:07 EST 2022
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords COVID-19
seroprevalence
health care workers
SARS-CoV-2 antibody
Language English
License This work is licensed under the Creative Commons Attribution 4.0 International License.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c532t-7b1b33255d758add21ef0bccc7b43e49fcf4f163d259ef691bcfbf0a706c89c73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0001-9523-9054
0000-0003-1284-7885
0000-0002-0270-1711
OpenAccessLink http://www.degruyter.com/doi/10.1515/cclm-2020-1236
PMID 32845861
PQID 2458276017
PQPubID 105421
PageCount 05
ParticipantIDs proquest_miscellaneous_2437849991
proquest_journals_2458276017
crossref_primary_10_1515_cclm_2020_1236
pubmed_primary_32845861
walterdegruyter_journals_10_1515_cclm_2020_123658122107
PublicationCentury 2000
PublicationDate 2020-08-26
PublicationDateYYYYMMDD 2020-08-26
PublicationDate_xml – month: 08
  year: 2020
  text: 2020-08-26
  day: 26
PublicationDecade 2020
PublicationPlace Germany
PublicationPlace_xml – name: Germany
– name: Berlin
PublicationTitle Clinical chemistry and laboratory medicine
PublicationTitleAlternate Clin Chem Lab Med
PublicationYear 2020
Publisher De Gruyter
Walter De Gruyter & Company
Publisher_xml – name: De Gruyter
– name: Walter De Gruyter & Company
References 2023033111431160648_j_cclm-2020-1236_ref_030
2023033111431160648_j_cclm-2020-1236_ref_003
2023033111431160648_j_cclm-2020-1236_ref_025
2023033111431160648_j_cclm-2020-1236_ref_004
2023033111431160648_j_cclm-2020-1236_ref_026
2023033111431160648_j_cclm-2020-1236_ref_005
2023033111431160648_j_cclm-2020-1236_ref_027
2023033111431160648_j_cclm-2020-1236_ref_006
2023033111431160648_j_cclm-2020-1236_ref_028
2023033111431160648_j_cclm-2020-1236_ref_021
2023033111431160648_j_cclm-2020-1236_ref_022
2023033111431160648_j_cclm-2020-1236_ref_001
2023033111431160648_j_cclm-2020-1236_ref_023
2023033111431160648_j_cclm-2020-1236_ref_002
2023033111431160648_j_cclm-2020-1236_ref_024
2023033111431160648_j_cclm-2020-1236_ref_007
2023033111431160648_j_cclm-2020-1236_ref_029
2023033111431160648_j_cclm-2020-1236_ref_008
2023033111431160648_j_cclm-2020-1236_ref_009
2023033111431160648_j_cclm-2020-1236_ref_020
2023033111431160648_j_cclm-2020-1236_ref_014
2023033111431160648_j_cclm-2020-1236_ref_015
2023033111431160648_j_cclm-2020-1236_ref_016
2023033111431160648_j_cclm-2020-1236_ref_017
2023033111431160648_j_cclm-2020-1236_ref_010
2023033111431160648_j_cclm-2020-1236_ref_011
2023033111431160648_j_cclm-2020-1236_ref_012
2023033111431160648_j_cclm-2020-1236_ref_013
2023033111431160648_j_cclm-2020-1236_ref_018
2023033111431160648_j_cclm-2020-1236_ref_019
References_xml – ident: 2023033111431160648_j_cclm-2020-1236_ref_020
  doi: 10.1001/jamainternmed.2020.4214
– ident: 2023033111431160648_j_cclm-2020-1236_ref_002
  doi: 10.7326/M20-1301
– ident: 2023033111431160648_j_cclm-2020-1236_ref_008
  doi: 10.1515/cclm-2020-0443
– ident: 2023033111431160648_j_cclm-2020-1236_ref_016
  doi: 10.1101/2020.03.16.20035014
– ident: 2023033111431160648_j_cclm-2020-1236_ref_021
  doi: 10.1001/jama.2020.14765
– ident: 2023033111431160648_j_cclm-2020-1236_ref_006
  doi: 10.1126/science.abc1227
– ident: 2023033111431160648_j_cclm-2020-1236_ref_007
  doi: 10.1093/labmed/lmaa025
– ident: 2023033111431160648_j_cclm-2020-1236_ref_024
  doi: 10.1038/s41591-020-0897-1
– ident: 2023033111431160648_j_cclm-2020-1236_ref_010
  doi: 10.1515/cclm-2020-0749
– ident: 2023033111431160648_j_cclm-2020-1236_ref_028
  doi: 10.1016/j.it.2020.03.007
– ident: 2023033111431160648_j_cclm-2020-1236_ref_019
  doi: 10.1001/jama.2020.11160
– ident: 2023033111431160648_j_cclm-2020-1236_ref_026
  doi: 10.1016/j.cell.2020.05.015
– ident: 2023033111431160648_j_cclm-2020-1236_ref_001
  doi: 10.1001/jama.2020.4683
– ident: 2023033111431160648_j_cclm-2020-1236_ref_014
  doi: 10.1016/j.cca.2020.04.026
– ident: 2023033111431160648_j_cclm-2020-1236_ref_013
  doi: 10.1001/jama.2020.8259
– ident: 2023033111431160648_j_cclm-2020-1236_ref_022
  doi: 10.1056/NEJMc2011599
– ident: 2023033111431160648_j_cclm-2020-1236_ref_012
  doi: 10.1093/cid/ciaa310
– ident: 2023033111431160648_j_cclm-2020-1236_ref_005
  doi: 10.1038/s41591-020-0913-5
– ident: 2023033111431160648_j_cclm-2020-1236_ref_015
  doi: 10.1515/cclm-2020-0473
– ident: 2023033111431160648_j_cclm-2020-1236_ref_030
  doi: 10.1515/cclm-2020-0880
– ident: 2023033111431160648_j_cclm-2020-1236_ref_023
– ident: 2023033111431160648_j_cclm-2020-1236_ref_003
  doi: 10.2807/1560-7917.ES.2020.25.10.2000180
– ident: 2023033111431160648_j_cclm-2020-1236_ref_025
  doi: 10.1101/2020.05.12.20098236
– ident: 2023033111431160648_j_cclm-2020-1236_ref_018
  doi: 10.1016/j.jcv.2020.104545
– ident: 2023033111431160648_j_cclm-2020-1236_ref_017
  doi: 10.1016/S1473-3099(20)30196-1
– ident: 2023033111431160648_j_cclm-2020-1236_ref_011
  doi: 10.2139/ssrn.3546052
– ident: 2023033111431160648_j_cclm-2020-1236_ref_009
  doi: 10.1016/j.cca.2020.05.050
– ident: 2023033111431160648_j_cclm-2020-1236_ref_029
  doi: 10.1515/cclm-2020-1096
– ident: 2023033111431160648_j_cclm-2020-1236_ref_027
  doi: 10.1101/2020.04.17.20061440
– ident: 2023033111431160648_j_cclm-2020-1236_ref_004
  doi: 10.2807/1560-7917.ES.2020.25.3.2000045
SSID ssj0015547
Score 2.543897
Snippet Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable...
Abstract Objectives The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses...
The ongoing outbreak of coronavirus disease (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses formidable challenges...
SourceID proquest
crossref
pubmed
walterdegruyter
SourceType Aggregation Database
Index Database
Publisher
StartPage 2107
SubjectTerms Adult
Antibodies
Antigens
Asymptomatic
Betacoronavirus - immunology
Biomedical engineering
Chemiluminescence
Coronaviridae
Coronaviruses
COVID-19
Female
Health care
health care workers
Health Personnel - statistics & numerical data
Health services
Humans
Immunoglobulin G
Immunoglobulin M
Infections
Italy
Luminescent Measurements
Male
Medical personnel
Middle Aged
Polymerase chain reaction
Respiratory diseases
Reverse transcription
Risk groups
SARS-CoV-2
SARS-CoV-2 antibody
Seroconversion
Seroepidemiologic Studies
seroprevalence
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Subpopulations
Viral diseases
Title SARS-CoV-2 serosurvey in health care workers of the Veneto Region
URI http://www.degruyter.com/doi/10.1515/cclm-2020-1236
https://www.ncbi.nlm.nih.gov/pubmed/32845861
https://www.proquest.com/docview/2458276017
https://search.proquest.com/docview/2437849991
Volume 58
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKJvHxMMH4KgwUJCQepmyNk9jOY6naTWgbaP3Q3qLEOZdJI0FdC4I_gL-bc2yn7Toh4CWKnCi27n453_m-CHmrBGMgQuUzJRI_ymTh50yfiCXAJQOeiEyfQ56eseNx9OEivmi1fq1ELS3m-YH8eWteyf9wFceQrzpL9h8423wUB_Ae-YtX5DBe_4rHw-750O9VE5_u43zV9WL2Deo8PpPdWJedrpvB6CxdGwwwQeGG-uY5TB1HXJ0ClyMpXQ-42rFgUaJd8Tf98J-uIDctoXTKjwnoMu6oosrKJlyyEfwDKMBkY4-nzctD-fkSUJ2vTJAZmG7e7iCC1mFwJtvdiLvavY9icv9otvihbzV2N6Qa6meRz5hJiz4AN8aXqVtWLMdiFX50TciaRrl2w6ZWXG9sBnFdN0PKqy9-vV5daGa57TlX_9nHdDA-OUlH_YvRHbJNUWChpNzuHr3vTxp_FCpddZset3hb_hNnOFz__rp6s2GzPCA732s6FTA1VFrRZkYPyY41Q7yuwdQj0oJyl9zrOc7vkrunltmPcedtYOYtYeZdlp6Bmadh5lmYeZXyEGaegZlnYPaEjAf9Ue_Yt503fBmHdO7zPMjDEK3NAs1J3AFpAKqTSyl5HoUQJUqqSKEmX6DxDIolQS5VrjoZ7zApEsnDp2SrrEp4TjzBhSgyRWUsaFQUnSwDBkUWZQEFCDqiTd45gqVfTYGVVBumSNpUkzbVpE01adtkz9EztT_hdUq131fHdfE2edM8Rlppv1dWQrXQ74RcaMs-aJNnhg_NVCGqZ7Fg-ITfYMxyjtuXE6NqrJH44s_LeknuL3-WPbI1ny3gFeqx8_y1BdlvpdmdYg
link.rule.ids 315,783,787,27936,27937
linkProvider Walter de Gruyter
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+serosurvey+in+health+care+workers+of+the+Veneto+Region&rft.jtitle=Clinical+chemistry+and+laboratory+medicine&rft.au=Plebani%2C+Mario&rft.au=Padoan%2C+Andrea&rft.au=Fedeli%2C+Ugo&rft.au=Schievano%2C+Elena&rft.date=2020-08-26&rft.pub=Walter+De+Gruyter+%26+Company&rft.issn=1434-6621&rft.eissn=1437-4331&rft.volume=58&rft.issue=12&rft.spage=2107&rft.epage=2111&rft_id=info:doi/10.1515%2Fcclm-2020-1236&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1434-6621&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1434-6621&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1434-6621&client=summon